These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16285330)

  • 21. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians.
    Nelson CR; Knapp DA
    Hypertension; 2000 Oct; 36(4):600-3. PubMed ID: 11040242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: use of individual and combination treatment.
    DeWilde S; Carey IM; Richards N; Whincup PH; Cook DG
    Heart; 2008 Jan; 94(1):83-8. PubMed ID: 17540684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians.
    Ubel PA; Jepson C; Asch DA
    J Gen Intern Med; 2003 Dec; 18(12):977-83. PubMed ID: 14687255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
    Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal patterns of antihypertensive medication use among elderly patients. The Cardiovascular Health Study.
    Psaty BM; Savage PJ; Tell GS; Polak JF; Hirsch CH; Gardin JM; McDonald RH
    JAMA; 1993 Oct; 270(15):1837-41. PubMed ID: 8105112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary prevention in coronary heart disease: goal achievement and drug prescribing.
    Giverhaug T; Bruland C; Trovik T
    Pharm World Sci; 2005 Dec; 27(6):472-4. PubMed ID: 16341957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-year follow-up of drug utilization for secondary prevention in coronary artery disease.
    Apikoglu Rabus S; Izzettin FV; Sancar M; Karakaya O; Kargin R; Yakut C
    Pharm World Sci; 2008 Dec; 30(6):753-8. PubMed ID: 18563622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia.
    Venkatason P; Zaharan NL; Ismail MD; Wan Ahmad WA; Mahmood Zuhdi AS
    Eur J Clin Pharmacol; 2018 Jul; 74(7):953-960. PubMed ID: 29582106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins.
    Enriquez JR; Pratap P; Zbilut JP; Calvin JE; Volgman AS
    Gend Med; 2008 Mar; 5(1):53-61. PubMed ID: 18420166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival prospects after acute myocardial infarction in the UK: a matched cohort study 1987-2011.
    Gitsels LA; Kulinskaya E; Steel N
    BMJ Open; 2017 Jan; 7(1):e013570. PubMed ID: 28119386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive medication prescribing in 27,822 elderly Canadians with diabetes over the past decade.
    McAlister FA; Campbell NR; Duong-Hua M; Chen Z; Tu K
    Diabetes Care; 2006 Apr; 29(4):836-41. PubMed ID: 16567824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. General practitioners choose within a narrow range of drugs when initiating new treatments: a cohort study of cardiovascular drug formularies.
    Buusman A; Kragstrup J; Andersen M
    Eur J Clin Pharmacol; 2005 Oct; 61(9):651-6. PubMed ID: 16187132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002.
    Teeling M; Bennett K; Feely J
    Br J Clin Pharmacol; 2005 Feb; 59(2):227-32. PubMed ID: 15676046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing prescribing of guideline-recommended medications for ischaemic heart diseases: a systematic review and meta-analysis of interventions targeted at healthcare professionals.
    Nguyen T; Nguyen HQ; Widyakusuma NN; Nguyen TH; Pham TT; Taxis K
    BMJ Open; 2018 Jan; 8(1):e018271. PubMed ID: 29326185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary prevention therapies for coronary heart disease in patients with type 2 diabetes: an audit.
    Sharma KK; Guptha S; Gupta R
    J Assoc Physicians India; 2012 Apr; 60():28-30. PubMed ID: 23029739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary prevention of ischaemic cardiac events.
    Gami A
    Clin Evid; 2006 Jun; (15):195-228. PubMed ID: 16973010
    [No Abstract]   [Full Text] [Related]  

  • 38. Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada.
    Johnson D; Jin Y; Quan H; Cujec B
    J Am Coll Cardiol; 2003 Oct; 42(8):1438-45. PubMed ID: 14563589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.
    Wan Md Adnan WA; Zaharan NL; Bennett K; Wall CA
    Br J Clin Pharmacol; 2011 Mar; 71(3):458-66. PubMed ID: 21284706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug prescription in the post-percutaneous coronary interventions period: results of the ECART study].
    Philippe F; Sebaoun A; Avierinos C; Julien G
    Ann Cardiol Angeiol (Paris); 2004 Jun; 53(3):131-6. PubMed ID: 15291168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.